Intervention

BIA 6-512

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions1

Lead sponsors shown1

Clinical trials

3 shown

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgNCT03097211 · 2006-07-17

Effect of BIA 6-512 at Steady-state on the Levodopa PharmacokineticsNCT03094156 · 2006-04-26

Tolerability and Steady-state Pharmacokinetics of BIA 6-512NCT03093389 · 2005-05-11

Common conditions

Parkinson Disease3

Leading sponsors

Bial - Portela C S.A.3

Trial status mix

COMPLETED3

Phase mix

PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.